Shots:

• Dicerna to receive $175M up front- $50M equity investment- $75M for first three years of collaboration and up to $375.5M/ target as development- regulatory and commercialization milestones with royalties on product sales
• Both the companies will retain rights to co-develop and co-commercialize candidates and will explore up to 30 liver cell targets for which Dicerna will be responsible to conduct & fund discovery & preclinical development into clinical for each target while Novo Nordisk to be responsible for all further developments
• The collaboration allows Novo Nordisk to access Dicerna’s GalXC RNAi platform for delivering clinical candidates targeting chronic liver disease- non-alcoholic steatohepatitis (NASH)- type 2 diabetes- obesity- and rare diseases

Click here to­ read full press release/ article | Ref: Novo Nordisk | Image: Finans